Skip to main content
BBLG logo

Bone Biologics Corporation

BBLGNASDAQHealthcareBiotechnology

$0.40Today:- (-)1Y −84.37%

As of Oct 16, 2026 close

Market cap
$696.42K
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.39$2.76
Volume (live)
-
Avg. volume (3M)
215.96K

Bone Biologics (BBLG) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Bone Biologics used $2.69M of cash in operating activities. Free cash flow was −$2.69M.

Bone Biologics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Bone Biologics Corporation (BBLG) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-3.11-4.11-8.95-1.48-1.61-1.82-3.42-4.43-7.05
Depreciation & Amortization0.000.000.000.000.000.000.000.000.00
Deferred Income Tax0.000.000.000.000.000.00-0.28-0.720.00
Stock Based Compensation0.260.190.150.270.210.060.050.52-0.58
Change in Working Capital0.17-0.150.13-0.17-0.320.400.140.150.94
Change in Accounts Receivable-0.010.000.000.000.000.000.000.000.00
Change in Accounts Payable0.090.090.260.00-0.370.33-0.06-0.070.00
Change in Other Working Capital0.07-0.24-0.12-0.170.500.070.210.210.94
Other Operating Activities0.00-0.05-0.89-2.180.501.000.260.383.37
Net Cash from Operating Activities-2.69-4.12-9.56-3.57-1.23-0.43-3.25-4.10-3.33
Investing Activities
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Financing Activities
Debt Repayment0.000.000.000.00-0.010.402.320.002.70
Common Stock Issued4.704.425.044.436.860.000.004.370.70
Dividends Paid0.00-3.210.000.000.000.000.000.000.00
Other Financing Activities0.005.020.000.00-0.010.000.000.000.00
Net Cash from Financing Activities4.704.425.044.437.900.402.324.373.40
Summary
Net Change in Cash2.010.30-4.510.866.68-0.02-0.930.270.07
Cash at Beginning of Period3.333.037.546.680.000.020.960.690.62
Cash at End of Period5.333.333.037.546.680.000.020.960.69
Free Cash Flow-2.69-4.12-9.56-3.57-1.23-0.43-3.25-4.10-3.33
Supplemental Disclosures
Interest Paid----0.01----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Bone Biologics Cash Flow

What is Bone Biologics's free cash flow?

Bone Biologics had negative free cash flow of $2.69M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does Bone Biologics pay dividends or buy back shares?

Bone Biologics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition